Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
About this study
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
- Condition
- Leukemia, Lymphoblastic, Acute, Pediatric
- Tested
- Sampling bone tissue and blood
- Sponsor
- Rennes University Hospital
Who can join
- Age
- 0 to 17 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 10
- Minimum age: 0 years
- Maximum age: 17 years
- Study condition: Leukemia, Lymphoblastic, Acute, Pediatric
- Under 18 years
- With established diagnosis of B-ALL
- Initial diagnosis made in the investigating centre
- Having received oral and written information about the protocol, or oral only if the patient is unable to read.
- Having signed a consent form if the patient is capable of giving informed written consent.
- Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
- Beneficiary of a social security scheme
Exclusion 3
- Isolated extramedullary involvement at inclusion
- Patient of childbearing age without effective contraception.
- Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Where
3 sites, 3 recruiting
CHU Angers
Angers, France
CHU Brest
Brest, France
CHU Rennes
Rennes, France
Contact
-
Elie COUSIN, Md
299284321 elie.cousin@univ-rennes.fr
-
marie-laure gervais, phd
299284321 marie-laure.gervais@chu-rennes.fr
Potential match only. Final eligibility is determined by the study team.